These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34469622)

  • 41. Willingness to vaccinate against COVID-19 in Australia.
    Dodd RH; Cvejic E; Bonner C; Pickles K; McCaffery KJ;
    Lancet Infect Dis; 2021 Mar; 21(3):318-319. PubMed ID: 32619436
    [No Abstract]   [Full Text] [Related]  

  • 42. Inclusion of Pregnant and Lactating Persons in COVID-19 Vaccination Efforts.
    Riley LE; Jamieson DJ
    Ann Intern Med; 2021 May; 174(5):701-702. PubMed ID: 33493013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. COVID-19 in the Caribbean.
    Burki TK
    Lancet Respir Med; 2021 Apr; 9(4):e46. PubMed ID: 33581745
    [No Abstract]   [Full Text] [Related]  

  • 44. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 45. COVID-19 vaccine hesitancy and resistance: Correlates in a nationally representative longitudinal survey of the Australian population.
    Edwards B; Biddle N; Gray M; Sollis K
    PLoS One; 2021; 16(3):e0248892. PubMed ID: 33760836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidemiology, not geopolitics, should guide COVID-19 vaccine donations.
    Bollyky TJ; Murray CJL; Reiner RC
    Lancet; 2021 Jul; 398(10295):97-99. PubMed ID: 34115978
    [No Abstract]   [Full Text] [Related]  

  • 47. The French public's attitudes to a future COVID-19 vaccine: The politicization of a public health issue.
    Ward JK; Alleaume C; Peretti-Watel P;
    Soc Sci Med; 2020 Nov; 265():113414. PubMed ID: 33038683
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Challenges facing COVID-19 vaccination in India: Lessons from the initial vaccine rollout.
    Pandey A; Sah P; Moghadas SM; Mandal S; Banerjee S; Hotez PJ; Galvani AP
    J Glob Health; 2021 Jun; 11():03083. PubMed ID: 34221355
    [No Abstract]   [Full Text] [Related]  

  • 50. Cultural competence in vaccine rollout: migrants would face difficulties accessing covid-19 vaccines.
    Waterman LZ
    BMJ; 2021 Jan; 372():n220. PubMed ID: 33500270
    [No Abstract]   [Full Text] [Related]  

  • 51. Invited Editorial. COVID-19 Vaccine: Hope and reality.
    Sheek-Hussein M; Abu-Zidan FM
    Afr Health Sci; 2020 Dec; 20(4):1507-1509. PubMed ID: 34394211
    [No Abstract]   [Full Text] [Related]  

  • 52. Acceptance of a COVID-19 Vaccine Before it is Available in China During the Pandemic.
    Xu J; Liu C
    Int J Public Health; 2021; 66():1604092. PubMed ID: 34744597
    [No Abstract]   [Full Text] [Related]  

  • 53. Wednesday, January 20, 2021.
    Hotez PJ
    Microbes Infect; 2021; 23(1):104775. PubMed ID: 33220444
    [No Abstract]   [Full Text] [Related]  

  • 54. Addressing the safety of hyaluronic acid dermal filler injections during the SARS CoV-2 pandemic worldwide vaccination.
    Buzzaccarini G; Borin M; Diffidenti B; Varì S; Di Gioia M; Albini M; Noventa M; Laganà AS
    J Plast Reconstr Aesthet Surg; 2021 Dec; 74(12):3443-3476. PubMed ID: 34588152
    [No Abstract]   [Full Text] [Related]  

  • 55. Tanzania's position on the COVID-19 pandemic.
    Mfinanga SG; Mnyambwa NP; Minja DT; Ntinginya NE; Ngadaya E; Makani J; Makubi AN
    Lancet; 2021 Apr; 397(10284):1542-1543. PubMed ID: 33864748
    [No Abstract]   [Full Text] [Related]  

  • 56. When should the UK lift its lockdown?
    Kirby T
    Lancet Respir Med; 2021 Apr; 9(4):e44-e45. PubMed ID: 33617780
    [No Abstract]   [Full Text] [Related]  

  • 57. Mass infection is not an option: we must do more to protect our young.
    Gurdasani D; Drury J; Greenhalgh T; Griffin S; Haque Z; Hyde Z; Katzourakis A; McKee M; Michie S; Pagel C; Reicher S; Roberts A; West R; Yates C; Ziauddeen H
    Lancet; 2021 Jul; 398(10297):297-298. PubMed ID: 34245669
    [No Abstract]   [Full Text] [Related]  

  • 58. WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic.
    Mallapaty S
    Nature; 2021 Jun; 594(7862):161-162. PubMed ID: 34089030
    [No Abstract]   [Full Text] [Related]  

  • 59. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 60. COVID-19 and vaccine hesitancy: A longitudinal study.
    Fridman A; Gershon R; Gneezy A
    PLoS One; 2021; 16(4):e0250123. PubMed ID: 33861765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.